Compare McKesson Corporation (MCK) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Norwegian Cruise Line Holdings Ltd — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B). The key difference: McKesson Corporation is far larger — about 15.3× Norwegian Cruise Line Holdings Ltd's market cap, and McKesson Corporation pays a 0.4% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| MCK | NCLH | |
|---|---|---|
Market Cap | $108.46B | $7.11B |
Volume | 712,607 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $25.02 |
52-Week Low | $725.17 | $14.12 |
Typical Hold Time | 74 Days | 68 Days |
Enterprise Value | $115.00B | $21.93B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% with bullish technical signals and strong earnings beats. The company shows improving fundamentals with $9.83B revenue in 2025 and net income of $423M, while maintaining attractive valuation metrics including a 9.39 P/E ratio. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, driven by better-than-expected revenue performance.
NCLH presents a compelling investment case with analyst consensus pointing to 35% upside to the $20.86 price target. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term debt), and competitive Caribbean pricing. The stock's outlook remains positive given consecutive earnings beats and management's pricing strategies to stabilize performance through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
